We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

CF Industries (NYSE:CF) -6.8% in Friday's trading as J.P. Morgan downgrades shares to Underweight from Neutral with a $75 ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J.P. Morgan analyst Mark Strouse maintained a Hold rating on Bloom Energy (BE – Research Report) yesterday and set a price target of $16.00.

Cautious Optimism for Deal Making. The general consensus is that we will likely see an increase in M&A and capital market transactions in the ...

Dozens of Massachusetts biotech leaders will be heading to San Francisco this upcoming week for the 2025 J.P. Morgan ...

Investing.com -- J.P. Morgan analysts have upgraded their rating for Aviva plc (LON: AV) to "overweight" from "neutral," ...